CeriBell, Inc.
Financials
Valuation Metrics
CeriBell, Inc.'s Market Cap is $925M. At end of 2025 it was $816M. Ranked #2498 of 3,121 in US market (top 80%), #1033 of 1,463 on NASDAQ (top 71%), #157 of 205 in Health Care Equipment & Services (top 77%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $925M | US#2,498/3,121 Sec#157/205 |
| Revenue | $102M | US#2,701/3,121 Sec#184/205 |
| Net Income | $-66M | US—/3,121 Sec—/205 |
| Total Assets | $166M | US#3,020/3,121 Sec#191/205 |
| Net Assets | $128M | US#2,777/3,121 Sec#174/205 |
| Employees | 327 | US#2,397/3,121 Sec#165/205 |
| Value | ||
| P/B | 7.21x | US#2,470/3,121 Sec#155/205 |
| P/S | 9.07x | US#2,662/3,121 Sec#181/205 |
| FCF Yield | -6.09% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -51.43% | US#2,689/3,121 Sec#169/205 |
| ROA | -39.67% | US#2,945/3,121 Sec#193/205 |
| Op. Margin | -68.62% | US#2,701/3,121 Sec#185/205 |
| Revenue Growth | 31.70% | US#406/3,121 Sec#24/205 |
| Financial Health | ||
| Debt Ratio | 29.64% | US#329/3,121 Sec#34/205 |
| Total Debt | $22M | US#2,746/3,121 Sec#171/205 |
| FCF | $-56M | US#2,538/3,121 Sec#179/205 |
| Cash | $33M | US#2,739/3,121 Sec#179/205 |
| Current Ratio | 9.18x | US#284/3,121 Sec#12/205 |
| Performance | ||
| 1Y Return | 94.03% | US#189/3,121 Sec#19/205 |
| 1M Return | -2.09% | US#614/3,121 Sec#70/205 |
| From 52W High | -4.92% | US#131/3,121 Sec#22/205 |
| 1Y MDD | -30.52% | US#1,458/3,121 Sec#66/205 |
| Trading | ||
| Volume | 708,227 shares | US#1,694/3,121 Sec#109/205 |
| Trading Value | $17M | US#1,966/3,121 Sec#134/205 |
| Per Share | ||
| EPS | $-1.74 | US—/3,121 Sec—/205 |
| BPS | $3.38 | US#2,444/3,121 Sec#157/205 |
Company Info
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.